InDex Pharmaceuticals Holding AB (publ) year-end report 2022
PK Study fully recruited”Given the dose selection in Q4 2023 our near-term focus remains on increasing the speed of site and patient recruitment and we look forward to seeing the results of our action plan bear fruit in 2023”, said Jenny Sundqvist, CEO of InDex Pharmaceuticals. Period October – December 2022 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –58.2 (–22.7) million · Result after tax amounted to SEK –56.3 (–22.8) million, corresponding to SEK –0.11 per share (–0.04) before and after dilution · Cash flow from operating activities